Skip to main content
Premium Trial:

Request an Annual Quote

Theradiag 2020 Revenues up 8 Percent

NEW YORK — Theradiag reported on Monday an 8 percent year-over-year increase in revenues for 2020 on strong sales of its theranostics products.

For the 12-month period ended Dec. 31, 2020, Theradiag's revenues rose to €10.4 million ($12.6 million) from €9.6 million the year before. Theranostics sales climbed almost 16 percent to €5.1 million from €4.4 million, with the company's Tracker line of therapeutic drug monitoring tests selling particularly well in the US, where the products are commercialized in collaboration with HalioDx.

In vitro diagnostics revenues, meanwhile, edged up 2 percent to €5.3 million from €5.2 million with €900,000 in sales of Theradiag's SARS-CoV-2 antigen tests and related products helping to offset the impact of nonrecurring instrumentation sales recorded in 2019.

At the end of 2020, Croissy Beaubourg, France-based Theradiag had cash totaling €3.5 million.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.